Coverart for item
The Resource Guidance for industry : safety, efficacy, and pharmacokinetic studies to support marketing of immune globuline intravenous (human) as replacement therapy for primary humoral immunodeficiency

Guidance for industry : safety, efficacy, and pharmacokinetic studies to support marketing of immune globuline intravenous (human) as replacement therapy for primary humoral immunodeficiency

Label
Guidance for industry : safety, efficacy, and pharmacokinetic studies to support marketing of immune globuline intravenous (human) as replacement therapy for primary humoral immunodeficiency
Title
Guidance for industry
Title remainder
safety, efficacy, and pharmacokinetic studies to support marketing of immune globuline intravenous (human) as replacement therapy for primary humoral immunodeficiency
Title variation
Safety, efficacy, and pharmacokinetic studies to support marketing of immune globuline intravenous (human) as replacement therapy for primary humoral immunodeficiency
Contributor
Subject
Language
eng
Cataloging source
GPO
Government publication
federal national government publication
Index
no index present
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
Label
Guidance for industry : safety, efficacy, and pharmacokinetic studies to support marketing of immune globuline intravenous (human) as replacement therapy for primary humoral immunodeficiency
Link
http://purl.access.gpo.gov/GPO/LPS111654
Instantiates
Publication
Note
  • Title from PDF title page (viewed on Apr. 21, 2009)
  • "June 2008."
Bibliography note
Includes bibliographical references (p. 14-15)
Carrier category
online resource
Carrier MARC source
rdacarrier
Color
one color
Content category
text
Content type MARC source
rdacontent
Dimensions
unknown
Extent
online resource (i, 15 p.)
Form of item
electronic
Media category
computer
Media MARC source
rdamedia
Other physical details
digital, PDF file.
Specific material designation
remote
System control number
  • (OCoLC)ocn318922997
  • (OCoLC)ocn506182858
System details
Mode of access: Internet at the FHA CDER. Web site. Address as of 4/21/09: http://www.fda.gov/cber/gdlns/igivimmuno.pdf ; current access isavailable via PURL
Label
Guidance for industry : safety, efficacy, and pharmacokinetic studies to support marketing of immune globuline intravenous (human) as replacement therapy for primary humoral immunodeficiency
Link
http://purl.access.gpo.gov/GPO/LPS111654
Publication
Note
  • Title from PDF title page (viewed on Apr. 21, 2009)
  • "June 2008."
Bibliography note
Includes bibliographical references (p. 14-15)
Carrier category
online resource
Carrier MARC source
rdacarrier
Color
one color
Content category
text
Content type MARC source
rdacontent
Dimensions
unknown
Extent
online resource (i, 15 p.)
Form of item
electronic
Media category
computer
Media MARC source
rdamedia
Other physical details
digital, PDF file.
Specific material designation
remote
System control number
  • (OCoLC)ocn318922997
  • (OCoLC)ocn506182858
System details
Mode of access: Internet at the FHA CDER. Web site. Address as of 4/21/09: http://www.fda.gov/cber/gdlns/igivimmuno.pdf ; current access isavailable via PURL

Library Locations

Processing Feedback ...